Monte Rosa Therapeutics (GLUE) Earnings Date & Reports

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

GLUE is expected to report earnings to fall 2.36% to -38 cents per share on August 06

Monte Rosa Therapeutics GLUE Stock Earnings Reports

Q2'26

Est.

$-0.38

Q1'26

Missed

by $0.03

Q4'25

Missed

by $0.10

Q3'25

Beat

by $0.03

Q2'25

Beat

by $0.02

The last earnings report on May 07 showed earnings per share of -38 cents, missing the estimate of -36 cents. With 832.82K shares outstanding, the current market capitalization sits at 1.40B.

View a ticker or compare two or three

Compare

GLUE

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for GLUE